Erdafitinib Treatment in Metastatic Urothelial Carcinoma - Petros Grivas
Petros Grivas and Alicia Morgans join in a conversation about the recently FDA accelerated approval of erdafitinib in metastatic bladder cancer for tumors that exhibit mutations active isoforms of FGFR 2 and FGFR3. Dr. Grivas discusses the companion biomarkers used in the determination of genomic sequencing of the tumor tissue exhibiting FGF reception mutations. The indication for erdafitinib (package insert) is in patients where the genomic alternations are present and the patient. has previously been treated with platinum-based chemotherapy. Dr. Grivas discusses the details of patient selection, treatment access and the details of FDA approved or cleared companion biomarker genomic tests.
Petros Grivas, MD Ph.D., Associate Professor, Clinical Director of Genitourinary Cancers Program, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.
FDA Approved Companion Diagnositc Tests
BALVERSA (erdafitinib) Package Inset: tablets, for oral use Initial U.S. Approval: 2019
Watch: Erdafitinib in Bladder Cancer - Arjun Balar
BALVERSA™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations
BALVERSA™ (erdafitinib) – Janssen Prescription Assistance. (2019). Retrieved from http://www.janssenprescriptionassistance.com/balversa-cost-assistance